Mr. Tao Chen is a serial entrepreneur with unique startup experience in both life science and IT industries. Currently at Paragon Genomics, Tao is leading a team of talented scientists and business professionals in developing and commercializing breakthrough targeted sequencing technologies. The Company’s patented target enrichment assay products have been adopted by more than one hundred NGS labs across the globe for various applications such as cancer liquid biopsy, inherited disease testing, drug discovery and agrigenomics. Before starting Paragon Genomics, Tao had over 15 years of technical and business experience in the life science industry, holding leadership positions from R&D, corporate development to product management at various organizations. In the past, Tao turned around a $100M genomic reagent business by launching several real-time PCR products within two years. Tao also played key roles in several important acquisitions and investment deals in the NGS space.
Liquid Biopsy Showcase: Paragon Genomics
Paragon Genomics develops and commercializes breakthrough target enrichment solutions for Next-Generation Sequencing (NGS).
A Unique Molecular Barcoding Technology for Cancer Liquid Biopsy
Molecular-barcoded and target-enriched NGS libraries can be constructed in just 3.5 hours with a single-tube workflow using CleanPlex UMI Technology to confidently detect ultralow-frequency variants down to 0.1% allele frequency.